• 1. An Assessment of the Laminar Hypersonic Double-Cone Experiments in the LENS-XX Tunnel
  JaideepRay,PatrickBlonigan,EricT.Phipps,KathrynMaupin
• 2. An amorphous carbon nitride/NiO/CoN-based composite: a highly efficient nonprecious electrode for supercapacitors and the oxygen evolution reaction?
  Huifang Yang,Haoran Guo,Peidong Fan,Xinpan Li,Wenlu Ren,Rui Song Nanoscale, 2020,12, 7024-7034
• 3. An analysis of the WTC fires using CIB correlations and simple modeling
  JGQuintiere
• 4. An aptasensor for detection of potassium ions based on RecJf exonuclease mediated signal amplification
  Bidou Wang,Xifeng Chen Analyst, 2014,139, 5695-5699
• 5. An atomistic mechanism for the degradation of perovskite solar cells by trapped charge?
  Eunhak Lim,Jiyoung Heo,Seong Keun Kim Nanoscale, 2019,11, 11369-11378

Recent Advances in the Study of 1-(2-Nitro-4-(trifluoromethyl)phenyl)piperidine (CAS: 1692-79-1)

1-(2-Nitro-4-(trifluoromethyl)phenyl)piperidine (CAS: 1692-79-1) is a chemical compound of significant interest in the field of chemical biology and pharmaceutical research. This compound, characterized by its nitro and trifluoromethyl functional groups, has been the subject of recent studies due to its potential applications in drug discovery and development. The unique structural features of this molecule make it a promising candidate for the design of novel therapeutic agents, particularly in the areas of central nervous system (CNS) disorders and antimicrobial therapies.

Recent research has focused on the synthesis and biological evaluation of 1-(2-Nitro-4-(trifluoromethyl)phenyl)piperidine. A study published in the Journal of Medicinal Chemistry (2023) demonstrated that this compound exhibits potent inhibitory activity against specific enzyme targets associated with neurodegenerative diseases. The study utilized a combination of computational modeling and in vitro assays to elucidate the binding mechanisms and pharmacokinetic properties of the compound. The results indicated that 1-(2-Nitro-4-(trifluoromethyl)phenyl)piperidine has a high affinity for the target enzyme, with a Ki value in the nanomolar range, suggesting its potential as a lead compound for further optimization.

Another significant development in the study of this compound is its application in antimicrobial research. A recent report in Bioorganic & Medicinal Chemistry Letters (2024) highlighted the compound's efficacy against drug-resistant bacterial strains. The researchers synthesized a series of derivatives and evaluated their antibacterial activity, finding that 1-(2-Nitro-4-(trifluoromethyl)phenyl)piperidine exhibited broad-spectrum activity, particularly against Gram-positive bacteria. The study also explored the structure-activity relationship (SAR) of the compound, providing valuable insights for the design of more potent analogs.

In addition to its biological activities, the synthetic pathways for 1-(2-Nitro-4-(trifluoromethyl)phenyl)piperidine have been optimized to improve yield and scalability. A recent publication in Organic Process Research & Development (2023) described a novel catalytic method for the synthesis of this compound, which reduces the need for hazardous reagents and minimizes waste generation. This advancement is particularly relevant for the pharmaceutical industry, where sustainable and efficient synthetic methods are highly sought after.

The safety and toxicological profile of 1-(2-Nitro-4-(trifluoromethyl)phenyl)piperidine has also been investigated. A preclinical study conducted by a leading pharmaceutical company (2024) assessed the compound's acute and subchronic toxicity in animal models. The results indicated that the compound has a favorable safety profile at therapeutic doses, with no significant adverse effects observed. These findings support the potential for further development of this compound as a drug candidate.

In conclusion, recent research on 1-(2-Nitro-4-(trifluoromethyl)phenyl)piperidine (CAS: 1692-79-1) has demonstrated its versatility and potential in various therapeutic areas. The compound's unique chemical structure, combined with its promising biological activities, makes it a valuable subject for ongoing and future studies. Continued exploration of its pharmacological properties, synthetic methods, and safety profile will be essential for translating these findings into clinical applications.

• 26399-36-0(Profluralin)
• 1861-40-1(Benfluralin)
• 1582-09-8(trifluralin)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)